Clinical Trials Logo

Dermatitis clinical trials

View clinical trials related to Dermatitis.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06461299 Completed - Perioral Dermatitis Clinical Trials

Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis

Start date: July 17, 2023
Phase: Phase 4
Study type: Interventional

A Single-Center Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis

NCT ID: NCT06458868 Completed - Psoriasis Clinical Trials

An Open-label Controlled Trial: Effectiveness of Balneotherapy in Palmoplantar Psoriasis and Contact Dermatitis.

Start date: June 1, 2014
Phase: N/A
Study type: Interventional

Patients who had an indication for phototherapy were included in this study. The treatment was used as a monotherapy protocol. The standard protocol for bathing PUVA involved applying 0.01% bath psoralen for 15 minutes, while the tap water group only received a tap water bath for 15 minutes and the salt water group received 3% salted (NaCl) water before UVA treatment.

NCT ID: NCT06427733 Completed - Stasis Dermatitis Clinical Trials

Green Banana Peel Extract for Stasis Dermatitis Treatment

Start date: February 2, 2024
Phase: Phase 1
Study type: Interventional

To develop and evaluate a pharmaceutical formula based on green banana peel extract for the treatment of stasis dermatitis.

NCT ID: NCT06412094 Completed - Atopic Dermatitis Clinical Trials

Use of a Mobile Health App in Managing Pediatric Atopic Dermatitis

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

A randomized controlled study in children with AD, divided into three groups: a control group without access to the app, an experimental observational group with the app, and an experimental interventional group with potential investigator supervision. Outcome measures included the SCORAD and the POEM scores.

NCT ID: NCT06361992 Completed - Atopic Dermatitis Clinical Trials

Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children

Start date: March 15, 2022
Phase: Phase 3
Study type: Interventional

To verify the efficacy and tolerability of Activated Piroctone Olamine (Blue Cap Foam, label volume 100 ml) by CATALYSIS, S. L. Madrid, applied in the management of all types of dermatitis (atopic, seborrheic, eczema) in patients with significant manifestations of the disease in varying areas of the body of varying extent and to assess differences in individual tolerability and the final effect in a group of selected patients aged 3 to 18 years.

NCT ID: NCT06214481 Completed - Atopic Dermatitis Clinical Trials

A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants

Start date: January 23, 2024
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the pharmacokinetics of rocatinlimab after single subcutaneous (SC) administration in healthy Chinese participants.

NCT ID: NCT06134505 Completed - Clinical trials for Diaper Dermatitis Healing

Evaluation of the Efficiency of Local Application of Bee Products in the Care of Diaper Dermatitis in Infants

Start date: December 24, 2022
Phase: N/A
Study type: Interventional

The aim of this study was to evaluate the local application of bee products in the care of diaper dermatitis in infants. 1. H1: Barrier cream 1, consisting of a mixture of propolis, beeswax, queen bee larva and plants oil used in the care of diaper dermatitis, is more effective in recovering diaper dermatitis than barrier cream 2 containing zinc oxide. 2. H2: Barrier cream 1, consisting of a mixture of propolis, beeswax, queen bee larva and plants oil used in the care of diaper dermatitis, is more effective in recovering diaper dermatitis than olive oil. 3. H3: Diaper Dermatitis Severity Assessment Scale scores are lower in babies who use barrier cream 1, which consists of a mixture of propolis, beeswax, queen bee larva and plants oil, in the care of diaper dermatitis, compared to babies who use barrier cream 2, which contains zinc oxide. 4. H4: Diaper Dermatitis Severity Assessment Scale scores are lower in babies who use barrier cream 1, which consists of a mixture of propolis, beeswax, queen bee larva and plants oil, in the care of diaper dermatitis, than babies who use olive oil.

NCT ID: NCT06085521 Completed - Atopic Dermatitis Clinical Trials

A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

Start date: January 26, 2022
Phase: Phase 2
Study type: Interventional

Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice daily oral LNK01001 dose A or LNK01001 dose B or matching placebo for 12 weeks.

NCT ID: NCT06073613 Completed - Psoriasis Clinical Trials

Periodontal Status in Patients With Chronic Skin Diseases

Start date: January 20, 2023
Phase:
Study type: Observational

Objective: This study aimed to evaluate and compare the periodontal status of chronic skin disease (CSD) patients with healthy controls. Material and method: 109 patients and 37 healthy subjects were included in this study. Parameters evaluated included bleeding on probing index (BOP), periodontal pocket depths (PPD), clinical attachment level (CAL), simplified debris index (DI), simplified calculus index (CI), and the presence of oral lesions. Clinical parameters were measured and compared in the two groups. The significant level was set at 0.05.

NCT ID: NCT06063044 Completed - Atopic Dermatitis Clinical Trials

Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children

Start date: January 1, 2018
Phase:
Study type: Observational

Allergic diseases in children are major public health concerns due to their widespread and rising prevalence. The most classic pathway to trigger allergy is type I allergy mediated by immunoglobulin E(IgE), but the role of immunoglobulin G4(IgG4) in allergic diseases is still worth exploring.we have collected the data of allergic patients aged 0-14 years for retrospective cross-sectional analysis to evaluate the positive rates of total IgE, HDM IgE, FS-IgE and FS-IgG4. Meanwhile, investigators screened out patients who were treated with FS-IgG4-guided elimination diets with/without probiotics for more than 3 months to clarify the role of FS-IgG4 in childhood allergic diseases by assessing the improvement of clinical symptoms before and after treatment.